dr10624
Recombinant proteinexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 22, 2022 (NCT05378893)
Timeline
Indications
Mechanism of action
GLP1R agonist
- Glucagon receptorAGONIST
GCGR agonist
- KlothoAGONIST
KL agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07050134 | N/A | Jul 1, 2025 | Fudan University, Zhejiang Doer Biologics Co., Ltd. |
| NCT07024212 | Phase 2 | Apr 22, 2025 | Zhejiang Doer Biologics Co., Ltd. |
| NCT06555640 | Phase 2 | Aug 1, 2024 | Zhejiang Doer Biologics Co., Ltd. |
| NCT05378893 | Phase 1 | Jun 22, 2022 | Huadong Medicine Co., Ltd., New Zealand Clinical Research, Zhejiang Doer Biologics Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zhejiang Doer Biologics Co., Ltd. | For profit | 4 | 3 | 3 | 2022 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Huadong Medicine Co., Ltd. | For profit | 1 | 0 | 1 | 2022 |
| New Zealand Clinical Research | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1